Milene Saavedra
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 30 | 2026 | 1164 | 3.000 |
Why?
| | Rhinitis | 9 | 2025 | 159 | 1.590 |
Why?
| | Sinusitis | 9 | 2025 | 221 | 1.500 |
Why?
| | Pseudomonas Infections | 10 | 2022 | 229 | 1.360 |
Why?
| | Pseudomonas aeruginosa | 12 | 2023 | 392 | 0.840 |
Why?
| | Olfaction Disorders | 4 | 2026 | 74 | 0.660 |
Why?
| | Azithromycin | 6 | 2020 | 101 | 0.610 |
Why?
| | Anti-Bacterial Agents | 10 | 2022 | 1942 | 0.530 |
Why?
| | Minimal Clinically Important Difference | 3 | 2026 | 35 | 0.480 |
Why?
| | C-Reactive Protein | 2 | 2018 | 429 | 0.480 |
Why?
| | Smell | 3 | 2026 | 129 | 0.470 |
Why?
| | Neutrophils | 6 | 2020 | 1133 | 0.460 |
Why?
| | Tobramycin | 5 | 2019 | 63 | 0.410 |
Why?
| | Aminophenols | 4 | 2024 | 204 | 0.400 |
Why?
| | Gene Expression Profiling | 4 | 2018 | 1792 | 0.400 |
Why?
| | Mycobacterium Infections, Nontuberculous | 3 | 2022 | 339 | 0.380 |
Why?
| | Chronic Disease | 10 | 2026 | 1827 | 0.370 |
Why?
| | Respiratory Mucosa | 2 | 2008 | 323 | 0.360 |
Why?
| | Prospective Studies | 10 | 2026 | 8123 | 0.310 |
Why?
| | Mycobacterium abscessus | 2 | 2022 | 110 | 0.300 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 7 | 2024 | 373 | 0.300 |
Why?
| | Radiographic Image Enhancement | 1 | 2009 | 57 | 0.290 |
Why?
| | Kruppel-Like Transcription Factors | 2 | 2008 | 83 | 0.270 |
Why?
| | RNA Precursors | 1 | 2008 | 155 | 0.250 |
Why?
| | Benzodioxoles | 3 | 2024 | 164 | 0.250 |
Why?
| | Radiology | 1 | 2009 | 175 | 0.250 |
Why?
| | Quality of Life | 5 | 2026 | 3200 | 0.230 |
Why?
| | Sputum | 4 | 2022 | 302 | 0.220 |
Why?
| | Administration, Inhalation | 3 | 2022 | 567 | 0.220 |
Why?
| | Biomarkers | 5 | 2022 | 4340 | 0.200 |
Why?
| | Forced Expiratory Volume | 6 | 2019 | 451 | 0.200 |
Why?
| | Food Preferences | 1 | 2025 | 126 | 0.200 |
Why?
| | Indoles | 2 | 2024 | 511 | 0.190 |
Why?
| | Medication Adherence | 2 | 2025 | 535 | 0.190 |
Why?
| | Leukocytes | 2 | 2018 | 301 | 0.180 |
Why?
| | Humans | 37 | 2026 | 146342 | 0.180 |
Why?
| | Lipopolysaccharides | 2 | 2020 | 861 | 0.170 |
Why?
| | Adult | 18 | 2026 | 41087 | 0.170 |
Why?
| | Self Efficacy | 1 | 2025 | 418 | 0.170 |
Why?
| | Quinolones | 4 | 2024 | 204 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2786 | 0.150 |
Why?
| | Aztreonam | 2 | 2016 | 12 | 0.150 |
Why?
| | Feedback | 1 | 2020 | 183 | 0.150 |
Why?
| | Colistin | 1 | 2019 | 10 | 0.150 |
Why?
| | Inflammation | 3 | 2022 | 2919 | 0.150 |
Why?
| | Iron | 1 | 2002 | 359 | 0.150 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 325 | 0.140 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 29 | 0.140 |
Why?
| | British Columbia | 1 | 2018 | 27 | 0.140 |
Why?
| | Mental Health | 1 | 2025 | 779 | 0.130 |
Why?
| | Endoscopy | 3 | 2026 | 316 | 0.130 |
Why?
| | Severity of Illness Index | 4 | 2024 | 2921 | 0.130 |
Why?
| | Male | 21 | 2026 | 73396 | 0.130 |
Why?
| | Anxiety | 1 | 2025 | 1125 | 0.130 |
Why?
| | Young Adult | 9 | 2026 | 14330 | 0.130 |
Why?
| | Morbidity | 1 | 2018 | 319 | 0.130 |
Why?
| | Disease Progression | 4 | 2019 | 2867 | 0.130 |
Why?
| | Female | 21 | 2026 | 79499 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 366 | 0.120 |
Why?
| | Drug Combinations | 3 | 2024 | 400 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 486 | 0.110 |
Why?
| | Interferons | 1 | 2016 | 186 | 0.110 |
Why?
| | Depression | 1 | 2025 | 1575 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2022 | 2791 | 0.100 |
Why?
| | Quorum Sensing | 1 | 2014 | 80 | 0.100 |
Why?
| | Interleukin-8 | 2 | 2020 | 268 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 974 | 0.100 |
Why?
| | Apoptosis | 1 | 2002 | 2439 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 2092 | 0.100 |
Why?
| | Lung | 5 | 2023 | 4122 | 0.090 |
Why?
| | Cytokines | 3 | 2015 | 2081 | 0.090 |
Why?
| | Virulence Factors | 1 | 2014 | 175 | 0.090 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 55 | 0.090 |
Why?
| | Neutrophil Activation | 1 | 2013 | 84 | 0.090 |
Why?
| | Wound Infection | 1 | 2013 | 60 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 102 | 0.090 |
Why?
| | Prognosis | 2 | 2018 | 4351 | 0.090 |
Why?
| | Promoter Regions, Genetic | 2 | 2008 | 1242 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Biofilms | 3 | 2014 | 288 | 0.090 |
Why?
| | Middle Aged | 11 | 2026 | 36619 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6073 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2599 | 0.080 |
Why?
| | Microbial Viability | 1 | 2011 | 83 | 0.080 |
Why?
| | Extracellular Space | 1 | 2011 | 118 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2024 | 11821 | 0.080 |
Why?
| | Enzyme Induction | 2 | 2008 | 87 | 0.080 |
Why?
| | Nontuberculous Mycobacteria | 2 | 2022 | 189 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2008 | 1224 | 0.080 |
Why?
| | Paranasal Sinuses | 2 | 2024 | 77 | 0.080 |
Why?
| | Colorado | 2 | 2018 | 4595 | 0.080 |
Why?
| | Pyridines | 2 | 2024 | 610 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2113 | 0.070 |
Why?
| | Protein Array Analysis | 1 | 2009 | 56 | 0.070 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1432 | 0.070 |
Why?
| | Nasal Polyps | 1 | 2009 | 59 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2023 | 901 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5439 | 0.070 |
Why?
| | Time Factors | 2 | 2018 | 7109 | 0.070 |
Why?
| | Burns | 1 | 2013 | 365 | 0.070 |
Why?
| | Mutation | 2 | 2021 | 4093 | 0.070 |
Why?
| | Spirometry | 1 | 2008 | 234 | 0.070 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 162 | 0.060 |
Why?
| | NF-kappa B | 2 | 2008 | 674 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2020 | 3647 | 0.060 |
Why?
| | Interleukins | 1 | 2008 | 248 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 752 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 617 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2008 | 759 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 526 | 0.060 |
Why?
| | Aspirin | 1 | 2009 | 405 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1038 | 0.060 |
Why?
| | Cell Line | 2 | 2008 | 2814 | 0.050 |
Why?
| | Phospholipases A | 1 | 2005 | 97 | 0.050 |
Why?
| | Cytosol | 1 | 2005 | 215 | 0.050 |
Why?
| | Cohort Studies | 2 | 2020 | 6077 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 1119 | 0.050 |
Why?
| | Drug Interactions | 2 | 2016 | 405 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 133 | 0.050 |
Why?
| | Pseudomonas | 1 | 2023 | 30 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2126 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 300 | 0.050 |
Why?
| | Pyrrolidines | 1 | 2023 | 127 | 0.050 |
Why?
| | Trans-Activators | 1 | 2005 | 372 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 260 | 0.040 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 120 | 0.040 |
Why?
| | HIV-1 | 1 | 2008 | 913 | 0.040 |
Why?
| | Self-Management | 1 | 2025 | 207 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2002 | 112 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 367 | 0.040 |
Why?
| | Protease Inhibitors | 1 | 2002 | 103 | 0.040 |
Why?
| | Chemokine CCL4 | 1 | 2020 | 31 | 0.040 |
Why?
| | Anti-HIV Agents | 1 | 2008 | 914 | 0.040 |
Why?
| | Chloroquine | 1 | 2020 | 54 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3416 | 0.040 |
Why?
| | Bronchi | 1 | 2002 | 263 | 0.040 |
Why?
| | Adolescent | 4 | 2026 | 22557 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 173 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 517 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 11 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2008 | 4118 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2002 | 449 | 0.040 |
Why?
| | Sirolimus | 1 | 2020 | 282 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.030 |
Why?
| | Phagocytosis | 1 | 2020 | 298 | 0.030 |
Why?
| | Survival Analysis | 2 | 2016 | 1378 | 0.030 |
Why?
| | Homozygote | 1 | 2018 | 197 | 0.030 |
Why?
| | Sex Factors | 1 | 2024 | 2107 | 0.030 |
Why?
| | Aminopyridines | 1 | 2018 | 128 | 0.030 |
Why?
| | Autophagy | 1 | 2020 | 290 | 0.030 |
Why?
| | Child | 3 | 2020 | 22693 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 610 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 429 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 385 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 41 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 829 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1879 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 201 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 543 | 0.030 |
Why?
| | Retrospective Studies | 4 | 2019 | 17438 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1888 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 52 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2008 | 633 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 77 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 970 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1077 | 0.020 |
Why?
| | Chlorides | 1 | 2014 | 138 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5899 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2016 | 399 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2013 | 31 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1543 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 198 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 354 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 28 | 0.020 |
Why?
| | Mice | 2 | 2023 | 18297 | 0.020 |
Why?
| | Risk Factors | 2 | 2016 | 10921 | 0.020 |
Why?
| | DNA | 2 | 2008 | 1421 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1036 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 447 | 0.020 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 2 | 0.020 |
Why?
| | Caspase 8 | 1 | 2009 | 48 | 0.020 |
Why?
| | Caspase 9 | 1 | 2009 | 54 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 399 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 382 | 0.020 |
Why?
| | Animals | 3 | 2023 | 38106 | 0.020 |
Why?
| | Drug Tolerance | 1 | 2009 | 100 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 76 | 0.020 |
Why?
| | HIV Core Protein p24 | 1 | 2008 | 32 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 558 | 0.020 |
Why?
| | Transcription Factor AP-1 | 1 | 2008 | 76 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5246 | 0.020 |
Why?
| | Up-Regulation | 1 | 2008 | 841 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 2005 | 78 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 59 | 0.010 |
Why?
| | Group IV Phospholipases A2 | 1 | 2005 | 46 | 0.010 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2004 | 25 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2005 | 90 | 0.010 |
Why?
| | Early Diagnosis | 1 | 2004 | 251 | 0.010 |
Why?
| | Drosophila | 1 | 2005 | 168 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 881 | 0.010 |
Why?
| | Actins | 1 | 2005 | 422 | 0.010 |
Why?
| | Transfection | 1 | 2005 | 916 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4580 | 0.010 |
Why?
| | Protein Binding | 1 | 2008 | 2244 | 0.010 |
Why?
| | Registries | 1 | 2010 | 2400 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1724 | 0.010 |
Why?
| | Aged | 2 | 2010 | 26432 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3545 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 1195 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2005 | 2675 | 0.010 |
Why?
| | Child, Preschool | 1 | 2004 | 11913 | 0.000 |
Why?
|
|
Saavedra's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|